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Will We Be?
T
hisdecadehasbeendishearteningto
diabetesscientists,notbecausetheir
scientiﬁcdiscoveryandprogresshas
slackened,butpreciselytheopposite.Sci-
entiﬁc journals are replete with new basic
and clinical research ﬁndings that ﬁre
imaginations about a better world for di-
abeticpatientsinthenearfuture.Funding
the research has been the big problem.
Funds that are so critical to our progress
on the road to preventing and curing di-
abetes have been drastically constrained
in the past several years by the National
Institutes of Health (NIH) and the Amer-
ican Diabetes Association (ADA) because
of budget shortfalls (wars and economic
downturns are expensive). The tragic
irony is all too clear. In a time of unparal-
leled accumulation of important new
knowledge and fresh scientiﬁc insights
into prevention and reversal of diabetes
complications, the ﬁnancial resources to
take full advantage of recent leaps in
knowledge have been hard to come by.
With the NIH being essentially ﬂat-
funded for the past several years, the re-
search community has lost ground to
inﬂation at this time of immense oppor-
tunity. While it is impossible for ADA to
take up all the slack, we recognize we
must protect our scientiﬁc future by
maintaining important ongoing research
efforts. The ADA Research Policy Com-
mittee (RPC) took steps this past year to
safeguard clinical translation of research
and to protect our most vulnerable re-
searchscientists.Thelatterarenewscien-
tists just beginning research careers as
wellasestablishedscientistscaughtinthe
crossﬁre of budget shortfalls as they at-
tempt to renew their awarded grants.
These steps include the following: 1) the
proportion of funds awarded to human-
based clinical projects was brought to
parity with funds awarded to basic sci-
ence projects and 2) support was priori-
tized for young scientists beginning their
careers and for meritorious established
scientists whose research programs have
been compromised by current economic
circumstances. To do this, the RPC reluc-
tantly decided to temporarily discontinue
new funding of established investigators
already receiving over $500,000 annually
for their personal research.
Several other good things have
evolved during this important decision
making. First, the RPC is constructing a
new strategic plan for its funding policies
and will use it for future decisions. The
scientiﬁc vision inherent in this plan will
position the RPC to formulate responses
to future challenges in a timely and pro-
active manner. Second, the ADA Execu-
tive Committee had an eye-opening
experience watching the struggles of
ADA-fundedscientistsandresolvedtoin-
crease ADA research funding signiﬁ-
cantly. While the ﬁnal dollar amounts are
still being hammered out by the Board of
Directors, the overall ADA strategic plan
written in 2008 is clearly committed to
increasing the current total ADA revenue
of $233 million to $300 million in the
year 2011. If this plan is successful, this
29% increase in revenue would result in
at least a comparable increase in research
funding by 2011. The ADA strategic plan
alsocommitstomaintainingitspercentile
funding of research applications by 2011
toalevelthatexceedstheprevailingfund-
ing percentile of NIH.
AllthatIhavewrittenabovewascom-
posedbeforetheveryrecentdramaticfalls
in stock market values across the globe. It
is impossible to know where things will
be in January, when the publication pro-
cess is ﬁnished and this editorial sees the
light of day. Clearly, the current ﬁnancial
gyrationswillimpacttheabilityofADAto
raise and even sustain current contribu-
tions to research. Nonetheless, it is rea-
sonable to believe that as markets recover
andasanewadministrationisinstalledin
theWhiteHousein2009,hopeisjustiﬁed
that funding for all NIH-funded research
will eventually be restored to reasonable
levels. History and conventional wisdom
tellusthatfailedmarkets,andallthatthey
affect in society, will eventually recover.
The message is to take heart, hold on a bit
tighter and even longer, and anticipate
better times in the future. In the mean-
time, ADA will conduct its business of
supporting clinical and basic support of
research designed to conquer diabetes to
the best of its ability, all the while ﬁrmly
believing that failure is not an option.
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